Publications

Show details

The pharmaceutical industry has grown in recent years to become one of the most important pillars in various regions of Switzerland, if not the crucial driver of the regional economy. This study by BAK Economics AG illustrates the various impact channels as exemplified by the biotechnology company Biogen, which is investing around CHF 1.5 billion in the construction of a next-generation biopharmaceutical production facility in Luterbach. This production facility in the canton of Solothurn will directly create some 600 new jobs. Aside from the 400 jobs in biopharmaceutical production, a further 200 will be created in the outsourced areas of building maintenance, cleaning and catering. On the basis of model calculations, BAK reckons that the Biogen plant will result in an additional growth potential of 1.5 to 2.0 percent of the cantonal gross domestic product in 2019, and that the Biogen investment will generate a gross value added of more than CHF 800 million in the whole of Switzerland.

Show details

Show details

The economic importance of the pharmaceutical industry manifests in many ways: over the past 25 years, its companies have created thousands of additional jobs, and now almost one Swiss franc in ten is generated along the value chains of their research, development and production activities. The real economic output of the pharmaceutical industry tripled in the last ten years and was responsible for over 40 percent of Swiss economic growth. The basis for this outstanding achievement is the enormous capacity for innovation and productivity, coupled with international competitiveness.

Show details

Show details

The most important facts and figures on Switzerland’s healthcare and pharma landscape